We are pleased to announce an important MEFISTO publication: Our article "Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis" has just been published in the Journal of Controlled Release.
Highlights of this publication include the following:
- Release of bevacizumab from PLGA microparticles can be controlled.
- Degradation of bevacizumab during in vitro release was observed.
- Bevacizumab-loaded microparticles reduce angiogenesis in a 3D cellular model.
- Complex biomimicking structures by 3D printing microparticles-loaded collagen.
This work involved 4 MEFISTO partners: The University of Santiago de Compostela, the UMC Utrecht, the Consiglio Nationale delle Ricerche Napoli and Geistlich Pharma joined forces for this great result.